Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
106
datasets available to search
ShareScore release 0.9.0
Dataset results
106 results for “BRAF inhibitors”
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
ClinicalTrials.gov study NCT01605162. IPD Sharing: Not stated. Countries: 1. Publications: 0.
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
ClinicalTrials.gov study NCT04673955. IPD Sharing: NO. Countries: 2. Publications: 0.
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
ClinicalTrials.gov study NCT02143999. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
ClinicalTrials.gov study NCT01603212. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations
ClinicalTrials.gov study NCT07178717. IPD Sharing: NO. Countries: 1. Publications: 0.
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
ClinicalTrials.gov study NCT04984369. IPD Sharing: NO. Countries: 1. Publications: 0.
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
ClinicalTrials.gov study NCT03543969. IPD Sharing: Not stated. Countries: 1. Publications: 0.
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
ClinicalTrials.gov study NCT04965220. IPD Sharing: YES. Countries: 1. Publications: 0.
CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers
GEO Series GSE308451. Homo sapiens. 90 samples. Type: Expression profiling by high throughput sequencing.
AhR activity directs BRAF inhibitors resistance in metastastic melanoma
GEO Series GSE104869. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
BRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (RNA-Seq)
GEO Series GSE261118. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
B-Raf inhibitors induce epithelial differentiation in BRAF mutant colorectal cancer cells
GEO Series GSE50791. Homo sapiens. 18 samples. Type: Expression profiling by array.
Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping [RNA-seq]
GEO Series GSE203545. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma
GEO Series GSE107576. Homo sapiens. 4 samples. Type: Non-coding RNA profiling by high throughput sequencing.
BRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation
GEO Series GSE261119. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309
GEO Series GSE96753. Homo sapiens. 22 samples. Type: Protein profiling by protein array.
Braf inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia, and exert anti-leukemic activity
GEO Series GSE63790. Homo sapiens. 24 samples. Type: Expression profiling by array.
Gene expression profiling of B9 cells in response to two classes of BRAF inhibitors
GEO Series GSE71109. Mus musculus. 5 samples. Type: Expression profiling by array.
BRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (ATAC-Seq)
GEO Series GSE261117. Homo sapiens. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers
GEO Series GSE302631. Mus musculus. 40 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.